Clinical Psychopharmacology · Paper A
Antipsychotic chemical classes
This classification matters because it predicts side-effect burden more reliably than mechanism alone, before checking full prescribing data. Antipsychotics are grouped by their chemical structure, and that chemical class predicts side-effect burden more reliably than knowing the drug's general mechanism alone. For example, imagine two antipsychotics with similar dopamine-blocking strength: one causes marked sedation, the other causes marked stiffness instead. In practice, their different chemical classes explain that difference.
First-generation, or typical, antipsychotics include phenothiazines, such as chlorpromazine, which are more sedating and cause more dry mouth and low blood pressure, and butyrophenones, such as haloperidol, which are high-potencyHow small a dose of a drug is needed to produce a given effect.Read more → and cause more movement side effects with less sedation. Second-generation, or atypical, antipsychotics are chemically varied but share a lower, faster-dissociating dopamine D2 blockade plus serotonin 5-HT2AA serotonin receptor subtype that many antipsychotic drugs block, thought to help their antidepressant and antipsychotic effect.Read more → blockade: examples include clozapine, olanzapine, quetiapine, and risperidone. Substituted benzamides, such as amisulpride, act relatively selectively on dopamine receptors and are prolactinA hormone, raised by some antipsychotic drugs, linked to milk production and periods stopping.Read more →-raising with minimal sedation. Picture a patient needing an antipsychotic with minimal sedation and minimal weight gain. In practice, knowing amisulpride's specific chemical class makes it a rational choice.
Antipsychotics are usually taught by generation, first-generation (typical) versus second-generation (atypical), but that split hides a more useful layer of detail: chemical structure. Two drugs from the same generation, or even with similar dopamine-blocking strength, can behave very differently at the bedside because of the specific chemical scaffold they are built on, and knowing that scaffold lets you predict a side-effect profile before you even look it up.
A chemical class groups antipsychotics by their underlying ring structure, phenothiazine, butyrophenone, thioxanthene, dibenzodiazepine, dibenzothiazepine, benzisoxazole, substituted benzamide, or diphenylbutylpiperidine, rather than by how new the drug is or how it is marketed. Put simply, it is the drug's molecular family tree, and family resemblance predicts behaviour.
For example, imagine two typical antipsychotics with roughly equal dopamine (a brain receptor that dopamine binds to) blocking ; one may sedate heavily while the other causes marked stiffness instead, purely because of their chemical class. The trap is assuming "typical" or "atypical" alone tells you what a drug will do. It does not: generation predicts the broad receptor pattern, but chemical class within that generation predicts the specific side-effect flavour a patient is likely to experience.
Phenothiazines, such as chlorpromazine, are a tricyclic (three-ring) chemical class that tend to be more sedating and cause more anticholinergic (dry mouth, blurred vision) and blood-pressure-lowering side effects. Within phenothiazines there are further subgroups: aliphatic (like chlorpromazine, more sedating), piperidine (like pericyazine, fewer movement side effects), and piperazine (like trifluoperazine, more potent at D2 with more movement side effects). Butyrophenones, such as haloperidol, are a chemically distinct high- class built on a fluorophenyl-butanone backbone, causing more extrapyramidal (movement-related) side effects such as stiffness and tremor, with comparatively less sedation than phenothiazines. Thioxanthenes, such as flupentixol and zuclopenthixol, closely resemble phenothiazines structurally but replace the ring nitrogen at position 10 with a carbon double-bonded to the side chain, producing cis and trans isomers with different potency; thioxanthenes generally sit between phenothiazines and butyrophenones in their sedation-versus-movement-side-effect profile.
Second-generation antipsychotics are not one chemical family; they share a pharmacological pattern, lower and faster-dissociating D2 blockade plus serotonin receptor blockade, while being built on quite different ring structures. Clozapine and olanzapine are dibenzodiazepines, quetiapine is a dibenzothiazepine (a related ring with a sulfur atom instead of one nitrogen), and risperidone is a benzisoxazole. Substituted benzamides, such as amisulpride and sulpiride, act relatively selectively on dopamine D2 and D3 receptors with minimal binding elsewhere, meaning minimal sedation and minimal burden, but a comparatively higher tendency to raise (a hormone that stimulates milk production). Suppose a patient needs an antipsychotic with low sedation and low weight-gain risk for a physically demanding job; knowing amisulpride's chemical class, not just that it is described as an atypical, makes it a rational, targeted choice rather than a guess. Pimozide belongs to a small class called diphenylbutylpiperidines, built on a four-ring fluorinated piperidine structure, giving it an unusually long compared with haloperidol's simpler single-ring structure, but also a distinct cardiac risk, interval prolongation, that requires baseline and monitoring electrocardiograms ().
It is easy to mistake generation for class: not every "typical" is a phenothiazine (haloperidol is a butyrophenone), and not every "atypical" behaves the same way (amisulpride's near-pure D2/D3 selectivity makes it behave more like a targeted, low-sedation drug than the broadly receptor-promiscuous clozapine, despite both being labelled second-generation). Thioxanthenes are commonly mistaken for phenothiazines because of their near-identical ring structure; the single nitrogen-to-carbon substitution is the differential point worth remembering, and it is what gives thioxanthenes their intermediate side-effect profile rather than a phenothiazine-identical one.
There is no diagnostic test for a chemical class itself, but recognising which class a prescribed drug belongs to is diagnostic in the sense of explaining a patient's side-effect pattern: a patient on a butyrophenone or high- phenothiazine presenting with stiffness and tremor is displaying an expected extrapyramidal pattern for that class, while unexplained flushing, low blood pressure, and sedation on a phenothiazine points to its and antihistaminergic burden rather than a new illness.
In practice, a clinician who knows a drug's chemical class can often predict its likely side-effect profile before checking detailed prescribing data, because sedation, movement effects, elevation, and metabolic risk all cluster along chemical-class lines more reliably than along generation lines alone. NICE and Maudsley Prescribing Guidelines both stress individualised antipsychotic choice based on side-effect profile and patient preference rather than a fixed first-line drug. Because different chemical classes carry different risks, initial workup and ongoing screening vary by class: butyrophenones and high- phenothiazines need closer movement-disorder assessment, dibenzodiazepines like clozapine need mandatory blood monitoring for agranulocytosis (a dangerous drop in white blood cells), and diphenylbutylpiperidines need monitoring for prolongation.
The classic trap is a question that names a drug and asks you to predict its side effect purely from being told it is "atypical" or "typical." The exam wants you to reach for the chemical class instead: a substituted benzamide like amisulpride predicts elevation with minimal sedation, a dibenzodiazepine like clozapine predicts agranulocytosis risk and mandatory monitoring, and a diphenylbutylpiperidine like pimozide predicts prolongation, none of which "atypical" alone would tell you.
Chemical class, phenothiazine, butyrophenone, thioxanthene, dibenzodiazepine, dibenzothiazepine, benzisoxazole, substituted benzamide, or diphenylbutylpiperidine, predicts an antipsychotic's likely sedation, movement, , and cardiac side-effect profile more reliably than generation label alone, and should guide both the choice of drug and the monitoring plan around it.